Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.24.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2024
Stockholders' Equity  
Summary of restricted stock award activity

Weighted Average

Number of

Grant Date Fair

    

Shares

    

Value  

Non-vested at December 31, 2023

1,316,120

$

6.88

Granted

5,346,306

1.89

Forfeited

(23,894)

6.28

Vested

(280,800)

8.40

Non-vested at September 30, 2024

6,357,732

$

2.62

Summary of restricted stock units activity

    

    

Weighted Average

Number of

Grant Date Fair

Shares

Value

Non-vested at December 31, 2023

 

615,884

$

2.77

Granted

2,200,000

1.84

Forfeited

(17,638)

2.25

Non-vested at September 30, 2024

 

2,798,246

$

2.04

Summary of stock option award activity

Weighted Average 

Remaining

Weighted Average 

 Contractual Life

    

Stock Options 

    

Exercise Price

    

(in years)

Outstanding as of December 31, 2023

127,000

$

8.88

8.60

Outstanding as of September 30, 2024

127,000

$

8.88

7.85

Vested and exercisable as of September 30, 2024

120,250

$

6.50

8.13

Summary of warrant activities

Weighted Average 

Remaining

Weighted Average 

Contractual Life

    

Warrants 

    

Exercise Price 

    

(in years)

Outstanding as of December 31, 2023

30,097,671

$

2.36

3.00

Granted

25,531,378

1.87

Exercised

(7,258,892)

Outstanding as of September 30, 2024

48,370,157

$

2.20

2.98

Summary of stock-based compensation expense

The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 ($ in thousands):

For the three months ended September 30, 

For the nine months ended September 30, 

    

2024

    

2023

    

2024

    

2023

Research and development

$

543

$

304

$

1,629

$

881

General and administrative

 

1,068

385

1,862

1,344

Total stock-based compensation expense

$

1,611

$

689

$

3,491

$

2,225